聚合酶链反应检测铜绿假单胞菌感染性角膜溃疡的实验研究及临床应用

目的：探索聚合酶链反应（PCR）技术对铜绿假单胞菌感染性角膜溃疡快速诊断的可行性。优越性及其在临床应用中的价值。方法：建立PCR检测标准铜绿假单胞菌方法，对兔铜绿假单胞菌感染性角膜溃疡模型研究并应用于临床，并与细菌培养做比较。结果：铜绿假单胞菌扩增出一条长504bp的阳性条带，其他常见细菌，人和兔正常角膜组织均为阴性，动物模型PCR敏感性为93.8%。特异性为100.0%；细菌培养敏感性为68.7%。特异性为93.7%。临床标本PCR阳性率为66.7%；细菌培养阳性率为38.1%。结论：PCR技术对快速检测实验室和临床标本中的铜绿假单胞菌具有重要的应用价值。     

可吸收性医用珊瑚人工骨的致突变性研究

目的评价珊瑚人工骨的遗传毒性。方法采用Ames试验;细胞染色体畸变试验和小鼠骨髓细胞微核试验。结果不同浓度的浸提液加与不加S9mix条件下Ames试验;细胞染色体畸变试验以及微核试验与阴性对照组比较无显著差异,结果为阴性。结论在本试验系统条件下,可吸收性珊瑚人工骨无致突变作用。     

影响糖尿病足坏疽愈合的因素及针对性护理研究

目的探讨针对影响糖尿病肢端坏疽患者愈合因素进行针对性的护理。方法在600例糖尿病足坏疽住院患者中随机抽取168例分成2组,根据2组患者血浆蛋白、动脉硬化下肢血流量、微循环障碍程度、患足骨质破坏情况、缺乏糖尿病足坏疽的防治知识进行分析,找出影响愈合的因素,并做好针对性的护理工作。结果168例糖尿病足坏疽患者,下肢血流量、足背动脉搏动及甲襞微循环比较,2组差异有显著性意义(P<0.05);2组足坏疽合并肾病、骨质破坏和血红蛋白改变情况比较,2组差异有显著性意义(P<0.05)。结论根据糖尿病足坏疽患者影响愈合的因素,进行针对性的护理,加快了糖尿病足坏疽患者的愈合速度,同时综合治疗有利于糖尿病足坏疽的早日愈合,可以减少截肢,提高了糖尿病足坏疽患者的生活质量。     

p53基因(今又生~)联合支气管动脉化疗治疗肺癌15例近期疗效观察

目的探讨瘤内注射或经支气管动脉灌注p53基因联合支气管动脉灌注化疗(BAI)治疗肺癌的安全性、疗效和给药途径。方法经病理证实的15例肺癌,首先在CT引导下经皮穿刺瘤内注射或经支气管动脉灌注p53基因(今又生~),2～5天后,行BAI灌注化疗药物;然后根据病情变化再次进行基因治疗和/或BAI。治疗后常规使用螺旋CT定期复查,评价治疗效果。结果全部15例患者均完成上述治疗,并接受随访2～11个月。有效率(CR+PR)46.7%(7/15),1例肺部肿块消失,6例肺部肿块缩小,3例纵隔淋巴结缩小,1例胸水减少,仅1例观察到肿瘤长大,14例临床症状有不同程度缓解93.3%(14/15)。p53治疗后6例出现发热(38℃～40℃),未观察到基因药物的其它严重副作用,无严重操作有关并发症出现。结论本研究结果初步显示,作为肿瘤综合治疗的一部分,p53基因治疗与BAI联合应用,是一种治疗肺癌安全、有效的方法,提高了BAI的治疗效果。经皮瘤内注射p53是否为一种较好的给药途径值得进一步探讨。     

The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire

We examine and refine the Fagerström Tolerance Questionnaire (FTQ; Fagerström, 1978). The relation between each FTQ item and biochemical measures of heaviness of smoking was examined in 254 smokers. We found that the nicotine rating item and the inhalation item were unrelated to any of our biochemical measures and these two items were primary contributors to psychometric deficiencies in the FTQ. We also found that a revised scoring of time to the first cigarette of the day (TTF) and number of cigarettes smoked per day (CPD) improved the scale. We present a revision of the FTQ: the Fagerström Test for Nicotine Dependence (FTND).     

4例活体部分小肠移植术后早期并发症的防治经验

目的总结4例活体部分小肠移植术后早期并发症（1月内）的防治办法，为进一步开展活体小肠移植提供经验。方法4例活体部分小肠移植术后1月内，早期并发症重点在于防治吻合血管血栓、出血、感染、排斥反应、移植肠功能障碍等。结果3例移植受体术后1月内分别发生出血倾向、急性排斥反应、感染、移植肠功能障碍等并发症，但经及时准确的诊断与治疗得以好转，移植肠存活及功能均良好。结论注重活体部分小肠移植术后对于早期并发症的预防及治疗，对于患者预后有重要意义。     

无创通气不同呼吸界面对COPD患者的生理学影响

目的 探讨无创正压通气(NPPV)时不同呼吸界面对慢性阻塞性肺疾病(COPD)急性加重期并呼吸衰竭患者的生理学影响.方法 选择30例COPD急性加重期并呼吸衰竭患者.无创正压通气时患者随机先后接受不同呼吸界面(面罩、鼻罩和鼻塞).动态观察不同呼吸界面时患者呼吸方式、血气分析和对呼吸界面耐受性等的差异.结果 (1)与自主呼吸相比,无创正压通气时三种不同呼吸界面均可改善患者的潮气量、分钟通气量和呼吸频率(P＜0.01),三种不同呼吸界面时的呼吸频率相似(P＞0.05),但面罩时的潮气量和分钟通气量比鼻罩时更高(P＜0.05);(2)与自主呼吸相比,无创正压通气时三种不同呼吸界面均可改善患者的动脉血气(P＜0.05),面罩和鼻塞时的PCO2比鼻罩时更低(P＜0.05);(3)患者均可耐受三种不同的呼吸界面,但患者对鼻罩的耐受性比面罩和鼻塞更好(P＜0.01).结论 本生理学研究证实了无创正压通气可改善COPD急性加重期并呼吸衰竭患者的呼吸方式和动脉血气,面罩和鼻塞时的疗效更佳,而鼻罩时的耐受性更好.     

Sudden Death and Staged Therapy for Hemodynamic Stabilization in Patients Enrolled in a Heart Transplantation Program

To investigate the impact of staged therapy for advanced heart failure on therapeutic endpoints, 236 consecutive patients (coronary artery disease/dilated cardiomyopathy in 61/175 patients, left ventricular ejection fraction 14%± 5%, New York Heart Association Class IIl/IIIIV in 102/79/55 patients, respectively) with advanced heart failure were prospectively followed. One hundred thirtyseven patients enrolled from January 1989 to December 1991 were treated conventionally with digoxin, furosemide, and low dose angiotension converting enzyme (ACE) inhibition. Patients refractory to this therapy underwent urgent heart transplantation. Ninetynine patients enrolled from January 1992 to August 1993 underwent staged therapy: stage 1: maximal tolerated ACE inhibition; stage 2: therapy with PGE₁ for preand afterload reduction to achieve hemodynamic stabilization; or stage 3: refractory patients bridged to heart transplantation with continuous outpatient dobutamine. Sudden death was defined as death within 1 hour of symptoms if heart failure symptoms remained stable over the previous 7 days. Conventionally treated patients were followed for 10 ± 9 months; patients who underwent staged therapy for 9 ±5 months. In the group of patients that underwent standard therapy, 39 of 137 (28%) patients died: 5 (13%) deaths occurred suddenly, and death due to progressive pump failure occurred in the remaining 34 (87%) patients. In the group of patients that underwent staged therapy, 25 of 99 (25%) patients died: 13 (52%) deaths occurred suddenly, and 12 (48%) deaths occurred due to progressive pump failure. Thus, patients who underwent staged therapy were at increased risk for sudden death (P = 0.01, relative risk 3.4, 95% confidence interval 1.2–9.7) but were at lower risk for death from pump failure (P = 0.009, relative risk 0.44, 95% confidence interval 0.22–0.84). In patients who underwent therapy with continuous outpatient PGE₁ (n = 7) or dobutamine (n= 21), risk for sudden death (P = NS by log rank test) did not increase. In conclusion, staged therapy significantly reduced death from pump failure; however, patients who could be stabilized and considered too well for heart transplantation were at increased risk for sudden death. Thus, overall survival did not improve. Of note, outpatient dobutamine did not increase the risk for sudden death.